Related Experiment Video
Updated: Sep 28, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
A phase II study of non-platinum based chemotherapy with paclitaxel and vinorelbine in non-small cell lung cancer
Panagiotis Ginopoulos1, Emanuel Kontomanolis, Dimitrios Kardamakis
1Department of Clinical Oncology, General Hospital of St Andreas, Tsertidou 1, Patras PC 26335, Greece. drginop@mail.otenet.gr
Introduction:
Paclitaxel and vinorelbine combination in previous untreated patients with stage IIIb-IV non-small cell lung cancer (NSCLC) as a phase II study.
Patients And Methods:
Thirty-four patients (4 patients with stage IIIb, 30 patients in stage IV), with median age 66 and performance status 0-1, were administered paclitaxel, 175 mg/m(2) in a 3-h infusion rate on day 1 and vinorelbine, 25 mg/m(2) in a 10-min infusion rate on days 1, and 8 with G-CSF and EPO support.
Results:
Among our 33 evaluable patients for toxicity 16 patients (48.4%) presented leukopenia and 15 patients (45.4%) presented anemia despite G-CSF and EPO administration. Two patients (6%) presented Grade III-IV peripheral neuropathy. The overall response rate was 67.7%; 5 patients (16.1%) showed complete response (2 patients stage IIIb) and 16 patients (51.6%) showed partial response (1 patient stage IIIb). The overall median survival time was 10 months (range 3-18 months) and the median disease-free survival was 9 months (range 3-15 months) with an 1-year survival time of 45.1% (14 patients).
Conclusion:
The results of the combination as 1st line treatment for patients with non-operable NSCLC are promising and should be further investigated.
